AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23672735 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided drainage (USD)
Number of subjects: 17
Study 23672735 — intervention group
Group type: COMPARATOR
Intervention: Surgical incision and drainage (I&D)
Number of subjects: 17
Study 21851929 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavior therapy (ICBT)
Number of subjects: 126
Study 21851929 — intervention group
Group type: COMPARATOR
Intervention: Cognitive behavioral group therapy (CBGT)
Number of subjects: 126
Study 19372341 — intervention group
Group type: EXPERIMENTAL
Intervention: Colloid preload (15 mL/kg hydroxyethyl starch (HES) 130/0.4 [Voluven 6%])
Number of subjects: 40
Study 19372341 — intervention group
Group type: COMPARATOR
Intervention: Coload (given when cerebrospinal fluid identified)
Number of subjects: 40
Study 16583194 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG-C preparation (polyethylene glycol solution plus contrast medium)
Number of subjects: 100
Study 16583194 — intervention group
Group type: COMPARATOR
Intervention: PEG preparation (polyethylene glycol solution)
Number of subjects: 100
Study 15340345 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg/day
Number of subjects: 90
Study 15340345 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg/day
Number of subjects: 90
Study 15340345 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg/day
Number of subjects: 90
Study 15340345 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 90
Study 11489000 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel (75 mg/m2) and Carboplatin (AUC 5)
Number of subjects: 1077
Study 11489000 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel (175 mg/m2 in 3 h) and Carboplatin (AUC 5)
Number of subjects: 1077
Study 9516568 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 60
Study 9516568 — intervention group
Group type: COMPARATOR
Intervention: 5% glucose (control)
Number of subjects: 60
Study 8041980 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 0.005 mg/kg p.o.
Number of subjects: 30
Study 8041980 — intervention group
Group type: COMPARATOR
Intervention: Lorazepam 0.03 mg/kg p.o.
Number of subjects: 30
Study 2656310 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestrinone 2.5 mg capsules three times weekly orally
Number of subjects: 100
Study 2656310 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestrinone 5.0 mg capsules twice weekly orally
Number of subjects: 100
Study 2656310 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestrinone 5 mg vaginal tablets three times weekly
Number of subjects: 100
Study 2656310 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous treatment for 24 months
Number of subjects: 100
Study 2656310 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuation at 1 year
Number of subjects: 100
Study 29899047 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone health coaching intervention delivered by nurses (4 sessions over 11 weeks)
Number of subjects: 577
Study 29899047 — intervention group
Group type: COMPARATOR
Intervention: Usual care (leaflet about COPD)
Number of subjects: 577
Study 28436307 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia
Number of subjects: 640
Study 28436307 — intervention group
Group type: COMPARATOR
Intervention: Local anesthesia
Number of subjects: 640
Study 26286593 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensorimotor training 2 times per week
Number of subjects: 58
Study 26286593 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensorimotor training 4 times per week
Number of subjects: 58
Study 26286593 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensorimotor training 6 times per week
Number of subjects: 58
Study 26286593 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 58
Study 23547490 — intervention group
Group type: EXPERIMENTAL
Intervention: Colgate Great Regular Flavor (0.83% MFP)
Number of subjects: 32
Study 23547490 — intervention group
Group type: EXPERIMENTAL
Intervention: Crest Pro‐Health (0.454% SnF)
Number of subjects: 32
Study 23547490 — intervention group
Group type: EXPERIMENTAL
Intervention: Colgate Total Clean Mint Toothpaste (0.3% triclosan/copolymer/0.22% NaF)
Number of subjects: 32
Study 21742096 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20 mg
Number of subjects: 17800
Study 21742096 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17800
Study 19854539 — intervention group
Group type: EXPERIMENTAL
Intervention: Naabak(R) eyedrops (preservative-free NAAGA)
Number of subjects: 0
Study 19854539 — intervention group
Group type: COMPARATOR
Intervention: Sodium chloride 0.9% (Larmabak(R))
Number of subjects: 0
Study 16732083 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose fentanyl (50 microg/kg)
Number of subjects: 350
Study 16732083 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose fentanyl (10 microg/kg)
Number of subjects: 350
Study 15623588 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel 75 mg/m2 every 21 days + prednisone 5 mg twice a day for a total of 10 cycles (TXT q 3w)
Number of subjects: 1006
Study 15623588 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel 30 mg/m2 days 1, 8, 15, 22, and 29 every 6 weeks + prednisone 5 mg twice a day for a total of 5 cycles (TXT qw)
Number of subjects: 1006
Study 15623588 — intervention group
Group type: COMPARATOR
Intervention: Mitoxantrone 12 mg/m2 every 21 days + prednisone 5 mg twice a day for a total of 10 cycles (MTZ q 3w)
Number of subjects: 1006
Study 11717659 — intervention group
Group type: EXPERIMENTAL
Intervention: Presumptive sexually transmitted disease treatment during pregnancy
Number of subjects: 4033
Study 11717659 — intervention group
Group type: COMPARATOR
Intervention: Iron/folate and referral for syphilis (control)
Number of subjects: 4033
Study 9158077 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy (Premarin 0.625 mg and Norgestrel 1 mg) for more than 1 year
Number of subjects: 97
Study 9158077 — intervention group
Group type: COMPARATOR
Intervention: Control group (51 untreated postmenopausal women)
Number of subjects: 97
Study 8198022 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin 20 mg/day plus bezafibrate 400 mg/day
Number of subjects: 34
Study 8198022 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin 40 mg/day plus bezafibrate 400 mg/day
Number of subjects: 34
Study 8198022 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin 20 mg/day
Number of subjects: 34
Study 8198022 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin 40 mg/day
Number of subjects: 34
Study 8198022 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin plus bezafibrate
Number of subjects: 34
Study 8198022 — intervention group
Group type: COMPARATOR
Intervention: Fluvastatin 40 mg/day plus cholestyramine 8 g/day
Number of subjects: 34
Study 3294021 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil 160 mg twice daily
Number of subjects: 20
Study 3294021 — intervention group
Group type: COMPARATOR
Intervention: Bendrofluazide 5 mg daily
Number of subjects: 20
Study 3294021 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil 160 mg twice daily + Bendrofluazide 5 mg daily
Number of subjects: 20
Study 3294021 — intervention group
Group type: COMPARATOR
Intervention: Bendrofluazide 5 mg daily + Verapamil 160 mg twice daily
Number of subjects: 20
Study 31719072 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabis-based medicine extract (CBME) supplied by CannTrust Inc., Canada, with a high-cannabidiol-low-tetrahydrocannabinol concentration, treated for 6 months.
Number of subjects: 30
Study 31719072 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 31719072 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabis-based medicine extract (CBME)
Number of subjects: 30
Study 28767525 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower Limb (LL) exercises
Number of subjects: 84
Study 28767525 — intervention group
Group type: COMPARATOR
Intervention: Conventional lumbar extensor (LE) exercises
Number of subjects: 84
Study 28767525 — intervention group
Group type: COMPARATOR
Intervention: Lumbar stabilization (LS) exercises
Number of subjects: 84
Study 25111038 — intervention group
Group type: EXPERIMENTAL
Intervention: Cord drainage (unclamped after cutting)
Number of subjects: 485
Study 25111038 — intervention group
Group type: COMPARATOR
Intervention: Control (cord left clamped)
Number of subjects: 485
Study 24130585 — intervention group
Group type: EXPERIMENTAL
Intervention: Test Dentifrice (with S. calva root extract)
Number of subjects: 80
Study 24130585 — intervention group
Group type: COMPARATOR
Intervention: Herbal Dentifrice (Arodent™)
Number of subjects: 80
Study 24130585 — intervention group
Group type: COMPARATOR
Intervention: Synthetic Dentifrice (Colgate®)
Number of subjects: 80
Study 24130585 — intervention group
Group type: COMPARATOR
Intervention: Control Dentifrice
Number of subjects: 80
Study 17012531 — intervention group
Group type: EXPERIMENTAL
Intervention: Vestibular rehabilitation (VR) self-management booklet
Number of subjects: 360
Study 17012531 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom control (SC) self-management booklet
Number of subjects: 360
Study 17012531 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 360
Study 12598435 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening and prophylactic treatment (measurement of anterior chamber depth and intraocular pressure, followed by laser iridotomy for those with occludable angles)
Number of subjects: 4725
Study 12598435 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 4725
Study 10407201 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated stimulus presentation
Number of subjects: 0
Study 10407201 — intervention group
Group type: COMPARATOR
Intervention: Stimulus duration
Number of subjects: 0
Study 7552933 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine, 20 mg once daily for 4 weeks
Number of subjects: 35
Study 7552933 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 4 weeks
Number of subjects: 35
Study 1664832 — intervention group
Group type: EXPERIMENTAL
Intervention: Temafloxacin 600 mg once daily
Number of subjects: 278
Study 1664832 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin 500 mg twice daily
Number of subjects: 278
Study 7194172 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 microgram ethinyl oestradiol
Number of subjects: 0
Study 7194172 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 microgram ethinyl oestradiol
Number of subjects: 0
Study 7194172 — intervention group
Group type: EXPERIMENTAL
Intervention: Triphasic formulation (ethinyl oestradiol and levonorgestrel)
Number of subjects: 0
Study 29874478 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise at 30 °C/40% RH
Number of subjects: 12
Study 29874478 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise at 20 °C/40% RH
Number of subjects: 12
Study 29874478 — intervention group
Group type: COMPARATOR
Intervention: Passive heat exposure at 30 °C/40% RH
Number of subjects: 12
Study 28466851 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental BMI (paternal and maternal)
Number of subjects: 307
Study 28466851 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal BMI
Number of subjects: 307
Study 28466851 — intervention group
Group type: EXPERIMENTAL
Intervention: Paternal BMI
Number of subjects: 307
Study 28466851 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental BMI
Number of subjects: 307
Study 26614481 — intervention group
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP)
Number of subjects: 1063
Study 26614481 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1063
Study 23130817 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin BC capsules plus corresponding deficient hematinics (for groups I, II, III, IV)
Number of subjects: 91
Study 23130817 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin BC capsules only (for group V)
Number of subjects: 91
Study 20947926 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-peritoneal paclitaxel
Number of subjects: 0
Study 20947926 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 18325887 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (Group 1)
Number of subjects: 165
Study 18325887 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil 0.1 microg kg(‐1) (Group 2)
Number of subjects: 165
Study 18325887 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil 0.2 microg kg(‐1) (Group 3)
Number of subjects: 165
Study 18325887 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil 0.3 microg kg(‐1) (Group 4)
Number of subjects: 165
Study 15569851 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP
Number of subjects: 258
Study 15569851 — intervention group
Group type: EXPERIMENTAL
Intervention: CRP
Number of subjects: 258
Study 15569851 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP and CRP screening together
Number of subjects: 258
Study 15569851 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP > 50 pmol/L and CRP > 0.84 mg/L
Number of subjects: 258
Study 12783696 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone (n = 10)
Number of subjects: 20
Study 12783696 — intervention group
Group type: COMPARATOR
Intervention: D & C (Control group, n = 10)
Number of subjects: 20
Study 10369709 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine supplementation (20 g free glutamine replacing 3.8 g of total nitrogen)
Number of subjects: 168
Study 10369709 — intervention group
Group type: COMPARATOR
Intervention: Standard feeds (without glutamine)
Number of subjects: 168
Study 10369709 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine supplementation
Number of subjects: 168
Study 10369709 — intervention group
Group type: COMPARATOR
Intervention: Standard feeds
Number of subjects: 168
Study 10369709 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine supplementation in surgical patients
Number of subjects: 168
Study 8763084 — intervention group
Group type: EXPERIMENTAL
Intervention: Subunit vaccine injected into the buttock or internal aspect of the thigh
Number of subjects: 1959
Study 8763084 — intervention group
Group type: COMPARATOR
Intervention: Inactivated whole-virus vaccine
Number of subjects: 1959
Study 8763084 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular injection
Number of subjects: 1959
Study 1868502 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (37.5-75 mg/day)
Number of subjects: 150
Study 1868502 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibopamine (150-300 mg/day)
Number of subjects: 150
Study 1868502 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 7066142 — intervention group
Group type: EXPERIMENTAL
Intervention: Methohexitone alone
Number of subjects: 100
Study 7066142 — intervention group
Group type: EXPERIMENTAL
Intervention: Methohexitone with fentanyl
Number of subjects: 100
Study 7066142 — intervention group
Group type: EXPERIMENTAL
Intervention: Althesin alone
Number of subjects: 100
Study 7066142 — intervention group
Group type: EXPERIMENTAL
Intervention: Etomidate with fentanyl
Number of subjects: 100
Study 7066142 — intervention group
Group type: EXPERIMENTAL
Intervention: Althesin with fentanyl
Number of subjects: 100
Study 30556939 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone/Salmeterol (FP/SAL)
Number of subjects: 300
Study 30556939 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone (FP)
Number of subjects: 300
Study 28975718 — intervention group
Group type: EXPERIMENTAL
Intervention: Febuxostat 40 mg (increased to 80 mg if serum UA level was ≥6.0 mg/dl on day 14)
Number of subjects: 314
Study 28975718 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 314
Study 24718916 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsupported sitting with eyes open
Number of subjects: 14
Study 24718916 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsupported sitting with eyes closed
Number of subjects: 14
Study 24718916 — intervention group
Group type: COMPARATOR
Intervention: Standing position with eyes open
Number of subjects: 14
Study 24341437 — intervention group
Group type: EXPERIMENTAL
Intervention: Consistent and positive parental disciplinary practices
Number of subjects: 48
Study 24341437 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with siblings and from single-parent families
Number of subjects: 48
Study 24341437 — intervention group
Group type: EXPERIMENTAL
Intervention: Children from two-parent families
Number of subjects: 48
Study 24341437 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with better bimanual performance
Number of subjects: 48
Study 22583875 — intervention group
Group type: EXPERIMENTAL
Intervention: A/V glasses
Number of subjects: 48
Study 22583875 — intervention group
Group type: COMPARATOR
Intervention: No distraction
Number of subjects: 48
Study 19221871 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based treatment (COMM)
Number of subjects: 139
Study 19221871 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinic-based treatment (CLINIC)
Number of subjects: 139
Study 19221871 — intervention group
Group type: COMPARATOR
Intervention: Healthy control children
Number of subjects: 139
Study 17451369 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide treatment
Number of subjects: 57
Study 15199353 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate aerobic exercise training for 3 months (G1)
Number of subjects: 52
Study 15199353 — intervention group
Group type: COMPARATOR
Intervention: Control group (G2)
Number of subjects: 52
Study 15199353 — intervention group
Group type: EXPERIMENTAL
Intervention: Detraining after 3 months of training (G1)
Number of subjects: 52
Study 11771983 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine (0.3 mg, i.v.)
Number of subjects: 9
Study 11771983 — intervention group
Group type: COMPARATOR
Intervention: Glycopyrrolate (0.2 mg, i.v.)
Number of subjects: 9
Study 9525445 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 800 microg/day
Number of subjects: 64
Study 9525445 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 1600 microg/day
Number of subjects: 64
Study 9525445 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 3200 microg/day
Number of subjects: 64
Study 9525445 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone 10 mg/day
Number of subjects: 64
Study 9525445 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 7698050 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical human recombinant basic fibroblast growth factor (bFGF) applied daily for 6 weeks, then twice a week for 12 weeks
Number of subjects: 17
Study 7698050 — intervention group
Group type: COMPARATOR
Intervention: Placebo applied daily for 6 weeks, then twice a week for 12 weeks
Number of subjects: 17
Study 7698050 — intervention group
Group type: EXPERIMENTAL
Intervention: bFGF
Number of subjects: 17
Study 7698050 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 2793774 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental intervention (training in job seeking with a problem-solving process emphasizing inoculation against setbacks and positive social reinforcement)
Number of subjects: 928
Study 2793774 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 928
Study 860200 — intervention group
Group type: COMPARATOR
Intervention: Ringer's lactate (RLS)
Number of subjects: 141
Study 860200 — intervention group
Group type: EXPERIMENTAL
Intervention: Ringer's lactate with albumin (ALB)
Number of subjects: 141
Study 31834588 — intervention group
Group type: EXPERIMENTAL
Intervention: Training Executive, Attention and Motor Skills (TEAMS)
Number of subjects: 52
Study 31834588 — intervention group
Group type: COMPARATOR
Intervention: Parent education and support (comparison intervention)
Number of subjects: 52
Study 30880441 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular ultrasound renal denervation (RDN)
Number of subjects: 146
Study 30880441 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 146
Study 30880441 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular ultrasound renal denervation (RDN) and Sham procedure
Number of subjects: 146
Study 27530106 — intervention group
Group type: EXPERIMENTAL
Intervention: Directives on opioid prescribing released by the Veterans Health Administration (VHA) or the Food and Drug Administration (FDA)
Number of subjects: 32200000
Study 25992918 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose prednisone (15 mg/d)
Number of subjects: 38
Study 25992918 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-dose prednisone (30 mg/d)
Number of subjects: 38
Study 25992918 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose prednisone (60 mg/d)
Number of subjects: 38
Study 25992918 — intervention group
Group type: COMPARATOR
Intervention: Standard HF care alone
Number of subjects: 38
Study 23364407 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA
Number of subjects: 267
Study 23364407 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 267
Study 20661580 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole for 2 months
Number of subjects: 144
Study 20661580 — intervention group
Group type: EXPERIMENTAL
Intervention: Triptorelin for 2 months
Number of subjects: 144
Study 20661580 — intervention group
Group type: COMPARATOR
Intervention: Control group (no medication)
Number of subjects: 144
Study 19565728 — intervention group
Group type: EXPERIMENTAL
Intervention: Compound PuHuang Granules
Number of subjects: 328
Study 19565728 — intervention group
Group type: COMPARATOR
Intervention: NaoXueShuan Tablets
Number of subjects: 328
Study 19565728 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 328
Study 16395298 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil 200 mg
Number of subjects: 11
Study 16395298 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil 400 mg
Number of subjects: 11
Study 16395298 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 15115949 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 25
Study 15115949 — intervention group
Group type: EXPERIMENTAL
Intervention: Zuclopenthixol
Number of subjects: 25